Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials

Roy T. Steigbigel, David A. Cooper, Hedy Teppler, Joseph J. Eron, Jose M. Gatell, Princy N. Kumar, Jurgen K. Rockstroh, Mauro Schlechter, Christine Katlama, Martin Markowitz, Patrick Yeni, Mona R. Loutfy, Adriano Lazzarin, Jeffrey L. Lennox, Bonaventura Clotet, Jing Zhao, Hong Wan, Rand R. Rhodes, Kim M. Strohmaier, Richard J. BarnardRobin D. Isaacs, Bach Yen T Nguyen

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.

Original languageEnglish
Pages (from-to)605-612
Number of pages8
JournalClinical Infectious Diseases
Volume50
Issue number4
DOIs
Publication statusPublished - Feb 15 2010

Fingerprint

Safety
Infection
Virus Diseases
Therapeutics
HIV
Pharmaceutical Preparations
Raltegravir Potassium

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection : Week 96 results of the benchmrk 1 and 2 phase III trials. / Steigbigel, Roy T.; Cooper, David A.; Teppler, Hedy; Eron, Joseph J.; Gatell, Jose M.; Kumar, Princy N.; Rockstroh, Jurgen K.; Schlechter, Mauro; Katlama, Christine; Markowitz, Martin; Yeni, Patrick; Loutfy, Mona R.; Lazzarin, Adriano; Lennox, Jeffrey L.; Clotet, Bonaventura; Zhao, Jing; Wan, Hong; Rhodes, Rand R.; Strohmaier, Kim M.; Barnard, Richard J.; Isaacs, Robin D.; Nguyen, Bach Yen T.

In: Clinical Infectious Diseases, Vol. 50, No. 4, 15.02.2010, p. 605-612.

Research output: Contribution to journalArticle

Steigbigel, RT, Cooper, DA, Teppler, H, Eron, JJ, Gatell, JM, Kumar, PN, Rockstroh, JK, Schlechter, M, Katlama, C, Markowitz, M, Yeni, P, Loutfy, MR, Lazzarin, A, Lennox, JL, Clotet, B, Zhao, J, Wan, H, Rhodes, RR, Strohmaier, KM, Barnard, RJ, Isaacs, RD & Nguyen, BYT 2010, 'Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials', Clinical Infectious Diseases, vol. 50, no. 4, pp. 605-612. https://doi.org/10.1086/650002
Steigbigel, Roy T. ; Cooper, David A. ; Teppler, Hedy ; Eron, Joseph J. ; Gatell, Jose M. ; Kumar, Princy N. ; Rockstroh, Jurgen K. ; Schlechter, Mauro ; Katlama, Christine ; Markowitz, Martin ; Yeni, Patrick ; Loutfy, Mona R. ; Lazzarin, Adriano ; Lennox, Jeffrey L. ; Clotet, Bonaventura ; Zhao, Jing ; Wan, Hong ; Rhodes, Rand R. ; Strohmaier, Kim M. ; Barnard, Richard J. ; Isaacs, Robin D. ; Nguyen, Bach Yen T. / Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection : Week 96 results of the benchmrk 1 and 2 phase III trials. In: Clinical Infectious Diseases. 2010 ; Vol. 50, No. 4. pp. 605-612.
@article{87b81a69a0be415a9d181cbf5478cbc9,
title = "Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials",
abstract = "BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.",
author = "Steigbigel, {Roy T.} and Cooper, {David A.} and Hedy Teppler and Eron, {Joseph J.} and Gatell, {Jose M.} and Kumar, {Princy N.} and Rockstroh, {Jurgen K.} and Mauro Schlechter and Christine Katlama and Martin Markowitz and Patrick Yeni and Loutfy, {Mona R.} and Adriano Lazzarin and Lennox, {Jeffrey L.} and Bonaventura Clotet and Jing Zhao and Hong Wan and Rhodes, {Rand R.} and Strohmaier, {Kim M.} and Barnard, {Richard J.} and Isaacs, {Robin D.} and Nguyen, {Bach Yen T}",
year = "2010",
month = "2",
day = "15",
doi = "10.1086/650002",
language = "English",
volume = "50",
pages = "605--612",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection

T2 - Week 96 results of the benchmrk 1 and 2 phase III trials

AU - Steigbigel, Roy T.

AU - Cooper, David A.

AU - Teppler, Hedy

AU - Eron, Joseph J.

AU - Gatell, Jose M.

AU - Kumar, Princy N.

AU - Rockstroh, Jurgen K.

AU - Schlechter, Mauro

AU - Katlama, Christine

AU - Markowitz, Martin

AU - Yeni, Patrick

AU - Loutfy, Mona R.

AU - Lazzarin, Adriano

AU - Lennox, Jeffrey L.

AU - Clotet, Bonaventura

AU - Zhao, Jing

AU - Wan, Hong

AU - Rhodes, Rand R.

AU - Strohmaier, Kim M.

AU - Barnard, Richard J.

AU - Isaacs, Robin D.

AU - Nguyen, Bach Yen T

PY - 2010/2/15

Y1 - 2010/2/15

N2 - BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.

AB - BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.

UR - http://www.scopus.com/inward/record.url?scp=75749107023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749107023&partnerID=8YFLogxK

U2 - 10.1086/650002

DO - 10.1086/650002

M3 - Article

C2 - 20085491

AN - SCOPUS:75749107023

VL - 50

SP - 605

EP - 612

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -